441 results on '"Shah, Keyur B."'
Search Results
2. Differences in outcomes of combined heart-liver transplantation by primary cardiac diagnosis
3. Racial Differences in Donor-Derived Cell-Free DNA and Mitochondrial DNA After Heart Transplantation, on Behalf of the GRAfT Investigators
4. Equitable Access to Advanced Heart Failure Therapies in the United States: A Call to Action
5. Abstract 17210: Re-Defining Antibody Mediated Rejection With Donor-Specific Antibodies and Graft Dysfunction, on Behalf of the GRAfT Investigators
6. The 2023 International Society for Heart and Lung Transplantation Guidelines for Mechanical Circulatory Support: A 10- Year Update
7. Biceps Tendon Rupture as an Early Manifestation of Hereditary Transthyretin Amyloidosis
8. Phenotypic Spectrum of Transthyretin Cardiac Amyloidosis in a Family: Impact of Mutation Zygosity and Sex
9. Abstract 14759: Combining High-Sensitivity Cardiac Troponin and Donor-Derived Cell-Free Dna to Diagnose Acute Heart Transplant Rejection, on Behalf of the Graft Investigators
10. Abstract 11627: Genetic Testing for Hereditary Amyloid Transthyretin Amyloidosis: Insights From the Compass Program
11. Abstract 9800: Racial Differences in Donor-Derived and Mitochondrial Cell-Free Dna Could Explain Inferior Outcomes in Black Heart Transplant Patients, on Behalf of the Graft Investigators
12. Outcomes after heart transplantation and total artificial heart implantation: A multicenter study
13. Predictive Value of Cardiopulmonary Exercise Testing Parameters in Ambulatory Advanced Heart Failure
14. Elevated AT1R Antibody and Morbidity in Patients Bridged to Heart Transplant Using Continuous Flow Left Ventricular Assist Devices
15. Predictors of Renal Failure in Patients Treated With the Total Artificial Heart
16. Neurologic Complications in Patients with Left Ventricular Assist Devices: Single Institution Retrospective Review
17. Impact of Socioeconomic Factors on Patient Desire for Early LVAD Therapy Prior to Inotrope Dependence
18. Determinants of Cardiorespiratory Fitness in Patients with Heart Failure Across a Wide Range of Ejection Fractions
19. Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy
20. Disease-Modifying Pharmacological Therapies for Transthyretin Cardiac Amyloidosis
21. HFSA/SAEM/ISHLT Clinical Expert Consensus Document on the Emergency Management of Patients with Ventricular Assist Devices
22. Left Ventricular Assist Device Outflow Graft Compression: Incidence, Clinical Associations and Potential Etiologies
23. Continuous-Flow Left Ventricular Assist Device–Related Gastrointestinal Bleeding
24. Equitable Access to Advanced Heart Failure Therapies in the United States – A Call to Action
25. The Total Artificial Heart
26. Usefulness of Estimated Plasma Volume at Postdischarge Follow-Up to Predict Recurrent Events in Patients With Heart Failure
27. Device Management and Flow Optimization on Left Ventricular Assist Device Support
28. Left ventricular assist devices versus medical management in ambulatory heart failure patients: An analysis of INTERMACS Profiles 4 and 5 to 7 from the ROADMAP study
29. Abstract 16945: Total Artificial Heart Implantation in Patients With Intractable Ventricular Arrhythmias
30. Abstract 17018: Left Ventricular Assist Device Failure With Total Artificial Heart Bridge to Heart Transplant
31. Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients: The ROADMAP Study 2-Year Results
32. Transcatheter Heart Valve Thrombosis in a Patient With a Left Ventricular Assist Device
33. Hospitalizations and Outcomes in Patients Implanted with the Total Artificial Heart and Discharged with a Portable Driver
34. Impact of INTERMACS Profile on Clinical Outcomes for Patients Supported With the Total Artificial Heart
35. A bridge-to-bridge approach to heart transplantation using extracorporeal membrane oxygenation and total artificial heart
36. Prospective Evaluation of Implantable Cardioverter-Defibrillator Lead Function During and After Left Ventricular Assist Device Implantation
37. Solving the Puzzle of the Hematologic-Left Ventricular Assist Device Interface One Piece at a Time
38. Exercise Capacity in Patients with the Total Artificial Heart
39. Multicenter study of universal prophylaxis versus pre‐emptive therapy for patients at intermediate risk (R+) for CMV following heart transplantation.
40. Transthyretin Cardiac Amyloidosis
41. Circulating microRNAs in cellular and antibody-mediated heart transplant rejection
42. Psychosocial assessment of candidates and risk classification of patients considered for durable mechanical circulatory support
43. Right Ventricular Dysfunction: Lessons Learned From Mechanical Circulatory Assist Devices
44. Abstract 15798: MicroRNA Profiles in Cardiac Transplantation Distinguish Antibody-Mediated and Cellular Rejection
45. Multicenter Evaluation of Octreotide as Secondary Prophylaxis in Patients With Left Ventricular Assist Devices and Gastrointestinal Bleeding
46. Infections in Patients with a Total Artificial Heart Are Common but Rarely Fatal
47. Higher levels of allograft injury in black patients early after heart transplantation
48. Percutaneous approach to left ventricular assist device decommissioning
49. Response by Shah et al to Letter Regarding Article, “False-Positive 99m Technetium-Pyrophosphate Scintigraphy in Two Patients With Hypertrophic Cardiomyopathy”
50. A Phase 2a dose‐escalation study of the safety, tolerability, pharmacokinetics and haemodynamic effects of BMS‐986231 in hospitalized patients with heart failure with reduced ejection fraction
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.